Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma-Reference-Cited by-同舟云学术

Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma

Published:2021-12-31 Issue:6 Volume:15 Page:397-405
ISSN:1881-7815
Container-title:BioScience Trends
language:en
Short-container-title:BST

Author:

Zhang Wei¹,Wang Yingying¹,Dong Xiang¹,Yang Bo²,Zhou Hongyuan¹,Chen Lu¹,Zhang Zewu¹,Zhang Qin¹,Cao Guangtai¹,Han Zhiqiang¹,Li Huikai¹,Cui Yunlong¹,Wu Qiang¹,Zhang Ti¹,Song Tianqiang¹,Li Qiang¹

Affiliation:

1. Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, China.

2. Department of Pathology, Tianjin Medical University Cancer Institute and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine,Health (social science)

Link

https://www.jstage.jst.go.jp/article/bst/15/6/15_2021.01517/_pdf

Reference38 articles.

1. 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209-249.

2. 2. Sugawara Y, Hibi T. Surgical treatment of hepatocellular carcinoma. Biosci Trends. 2021; 15:138-141.

3. 3. Borzio M, Dionigi E, Rossini A, et al. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. Hepatology. 2018; 67:2215-2225.

4. 4. Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011; 56:2491-2496.

5. 5. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009; 198:333-339.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sialylated glycoproteins and sialyltransferases in digestive cancers: Mechanisms, diagnostic biomarkers, and therapeutic targets;Critical Reviews in Oncology/Hematology;2024-05

2. A Retrospective Study on Predicting Recurrence of Intermediate-Stage Hepatocellular Carcinoma After Radical Therapy;Journal of Hepatocellular Carcinoma;2024-01

3. Mass spectrometry analysis of intact protein N-glycosylation signatures of cells and sera in pancreatic adenocarcinomas;Journal of Zhejiang University-SCIENCE B;2024-01

4. Low expression of miR125a-5p predicts sensitivity to sorafenib by upregulating STAT3 and HTATIP2 in hepatocellular carcinoma;2023-12-19

5. Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol;BMJ Open;2023-09